Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.

Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes. Abstract Text:

    kazunari kondoKazunari Kondo,hiroyuki ochiHiroyuki Ochi,tamae matsumotoTamae Matsumoto,hiroyuki yoshikawaHiroyuki Yoshikawa,tadahito kandaTadahito Kanda,

    Infection with human papillomavirus 16 (HPV16), which is one of the 15 types of HPV causally associated with cervical cancer and accounts for 50% of the cases, can be prevented in a type-specific manner by an HPV16 virus-like particle (VLP) vaccine comprised of particles of the L1 protein alone. We attempted to modify the VLP vaccine by inserting the HPV16 L2-peptides including cross-neutralization epitopes into the L1 polypeptide. The chimeric L1 had, between L1 amino acids (aa) 430 and 433, the L2 sequence of aa 18-38, 56-75, or 96-115 (with the replacements of S at aa 101 and T at aa 112 with L and S, respectively). The three chimeric L1s were each expressed from the recombinant baculovirus in insect Sf9 cells, and the resultant VLPs were characterized. The chimeric VLPs were shown to present the L2-peptides on their surface. By immunizing rabbits with the VLPs, it was shown that they retained capability to induce the antibody neutralizing HPV16 and acquired capability to elicit antibodies cross-neutralizing the infectious HPV18, 31, 52, and 58 pseudovirions. Although the cross-neutralizing titers were lower than the type-specific neutralizing titer, the results suggest that the chimeric VLPs have potential to serve as a vaccine candidate for a broad spectrum of high-risk HPVs. J. Med. Virol. 80:841-846, 2008. (c) 2008 Wiley-Liss, Inc.

    Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes. Publishing Authors By Initials

    k kondoK Kondo,h ochiH Ochi,t matsumotoT Matsumoto,h yoshikawaH Yoshikawa,t kandaT Kanda,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes. Journal Published:

    PUBLICATION TYPE: Journal Article

    Journal: Journal of medical virology

    VOLUME: 80

    Page Numbers: 841-6

    Journal Abbreviation: J. Med. Virol.

    ISSN: 0146-6615

    DAY: 2

    MONTH: May

    YEAR: 2008

    Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 7705876

    Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes. Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes. Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.

    AFFILIATION: Center for Pathogen Genomics, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan.

    Country: United States

    United States Research PublicationUnited States Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: J Med Virol

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News